WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • WJPPS: MARCH ISSUE PUBLISHED
  • March Issue has been successfully launched on 1 March 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

Abstract

EVALUATION OF INFUSION RELATED REACTIONS AND RISK FACTORS ASSOCIATED WITH TRASTUZUMAB INFUSION

*G. Sathyaprabha, Chinju Rajan and Sneha Elizabeth

ABSTRACT

Trastuzumab is a humanized monoclonal antibody used for the treatment of Human Epidermal Growth Factor Receptor-2 overexpressed breast cancer. Like many Monoclonal antibodies, Trastuzumab is associated with Infusion Related Reaction (IRRs). The incidence of IRR varies widely between reports. Materials and Methods: A retrospective chart review of Breast cancer patients who treated with Trastuzumab was conducted. The objective was to find out the incidence and risk factors associated with Trastuzumab infusion. Results: A total of 65 patients who received Trastuzumab (672 doses) were evaluated. Two reactions were observed in two patients, resulting in an incidence of 3% of patients and 0.29% of total doses. All the reactions were of Grade 2. The infusion related reactions produced were effectively managed by administering supportive medications. By univariate regression analysis, BMI was found to be a risk factor for IRRs. From the analysis of premedications it was found that the use of Dexamethasone as premedications may not be required after the first two infusions of Trastuzumab. Conclusion: The results support that infusion related reactions produced mild to moderate in severity and were effectively managed with supportive medications. The infusion duration of 45 minutes ± 5 minute was considered safe from the study. This study also supports omitting the steroid as a premedication after the first two infusions of Trastuzumab. Furthur evaluation of Trastuzumab doses are necessary to find out the risk factors behind the IRRs.

Keywords: Trastuzumab, Infusion related Reactions, Body mass index, Dexamethasone.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More